Imageable polymers
The present invention relates to hydrogels comprising 1,2-diol or 1,3-diol groups acetalized with a radiopaque species of one or more covalently bound radiopaque halogens which are imageable during embolization therapy. The invention further relates to methods of making radiopaque polymers and radiopaque hydrogel microspheres to provide an imageable drug delivery system.
1. Microspheres comprising a polymer formed from an acrylamido polyvinyl alcohol-co-acrylamido-2-methylpropane sulfonate hydrogel polymer, the polymer having a structure of formula I or II
wherein X is formula III:
wherein Z is a linking group, or is absent, such that the phenyl group is bonded to the cyclic acetal;
if Z is present, then Z is selected from the group consisting of C 1-6 alkylene, C 1-6 alkoxylene or C 1-6 alkoxyalkylene;
Hal is 1,2,3 or 4 covalently attached radiopaque iodines; and
J is —CH 2 — or a bond.
2. The microspheres according to claim 1 wherein the hydrogel polymer comprises greater than 10% iodine by dry weight.
3. The microspheres according to claim 1 wherein the microspheres have a mean diameter size range of from 10 to 2000 μm.
4. The microspheres according to claim 1 having a mean radiopacity of 500 HU or greater.
5. The microspheres according to claim 1 wherein the hydrogel polymer has a net charge at physiological pH.
6. A composition comprising the microspheres according to claim 1 and a therapeutic agent wherein the therapeutic agent is absorbed into the hydrogel polymer.
7. A composition according to claim 6 wherein the therapeutic agent is electrostatically held in the hydrogel polymer and elutes from the hydrogel polymer in electrolytic media.
8. The microspheres according to claim 1 for use in embolization of a blood vessel.
9. A composition according to claim 6 for use in embolization of a blood vessel.
10. The microspheres according to claim 1 , wherein the hydrogel polymer comprises an iodinated aromatic group comprising 1, 2, 3, or 4 covalently bound iodines.
11. The microspheres according to claim 10 , wherein the aromatic group comprises a phenyl group covalently attached 1, 2, 3, or 4 iodines.
12. A composition according to claim 6 , wherein the therapeutic agent is selected from doxorubicin, epirubicin, sorafenib, sunitinib, vandetinib, miriplatin, topotecan and irinotecan.